Pharmacokinetics of nifedipine in Taiwanese

Biopharmaceutics and Drug Disposition

Volumn 25, Issue 2, 2004, Pages 77-84

  Chien, Shu Chen ^a   Uang, Yow Shieng ^a   Lin, Hsiu Yi ^a   Hsu, Kuang Yang ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Nifedipine; Pharmacokinetics; Taiwanese

Indexed keywords

NIFEDIPINE;

ADULT; AREA UNDER THE CURVE; BIOEQUIVALENCE; CALCULATION; COMPUTER PROGRAM; CONTROLLED STUDY; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; ETHNIC DIFFERENCE; ETHNOLOGY; HUMAN; HUMAN EXPERIMENT; INDIAN; MALE; MATHEMATICAL ANALYSIS; MEXICO; NORMAL HUMAN; RETROSPECTIVE STUDY; REVIEW; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TAIWAN; UNITED KINGDOM; UNITED STATES; VOLUNTEER;

ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CAPSULES; EUROPEAN CONTINENTAL ANCESTRY GROUP; HALF-LIFE; HUMANS; MALE; NIFEDIPINE; RETROSPECTIVE STUDIES; THERAPEUTIC EQUIVALENCY;

EID: 1842525012     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.386     Document Type: Review

References (34)

1. Robertson RM, Robertson D. Drugs used for the treatment of myocardial ischemia. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. Hardman JG, Limbird LE (eds). McGraw-Hill: 1996: 768-769.
2. Foster TS, Hamann SR, Richards VR, Bryant PJ, Graves DA, McAllister RG. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J Clin Pharmacol 1983; 23: 161-170.
3. Kondo S, Kuchiki A, Yamamoto K, Akimoto K, Takahashi K. Identification of nifedipine metabolites and their determination by gas chromatography. Chem Pharm Bull 1980; 28: 1-7.
4. Rämsch KD, Graefe KH, Scherling D, Sommer J, Ziegler R. Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine and nimodipine. Am J Neph 1986; 6(suppl 1): 73-80.
5. Castañeda-Hernández G, Hoyo-Vadillo C, Palma-Aguirre A, Flores-Murrieta FJ. Pharmacokinetics of oral nifedipine in different populations. J Clin Pharmacol 1992; 32: 140-145.
6. Kleinbloesem CH, van Brummelen P, Faber H, Danhof M, Vermeulen NPE, Breimer DD. Variability in nifedipine pharmacokinetics and dynamics: A new oxidation polymorphism in man. Biochem Pharmacol 1984; 33: 3721-3724.
7. Hoyo-Vadillo C, Castañeda-Hernández G, Herrera JE, et al. Pharmacokinetics of oral nifedipine: Relevance of the distribution phase. J Clin Pharmacol 1989; 29: 251-256.
8. Horster FA, Duhm B, Maul W, Medenwald H, Patzschke K, Wegner LA. Clinical investigations of the pharmacokinetics of radioactively marked 1,4-dihydro-2, 6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine dicarboxylic acid dimethyl ester. Arzneimittelforsch 1972; 22: 330-334.
9. Ahsan CH, Renwick AG, Waller DG, Challenor VF, George CF, Amanullah M. The influences of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993; 54: 329-338.
10. Sowunmi A, Radhid TJ, Akinyinka OO, Rewick AG. Ethnic differences in nifedipine kinetics: Comparisons between Nigerians, Caucasians, and South Asians. Br J Clin Pharmacol 1995; 40: 489-493.
11. Renwick AG, Robertson DRC, Macklin B, Challenor VF, Waller DG, George CF. The pharmacokinetics of oral nifedipine-a population study. Br J Clin Pharmacol 1988; 25: 701-708.
12. Renwick AG, Le Vie J, Challenor VF, Waller DG, Gruchy B, George CF. Factors affecting the pharmacokinetics of nifedipine. Eur J Clin Pharmacol 1987; 32: 351-355.
13. Rietbrock N, Kausch M, Engelhardt M, Woodcock BG. Nonbioequivalence of sublingual nifedipine. Br J Clin Pharmacol 1987; 23: 589-590.
14. Kleinbloesem CH, van Harten J, van de Linde JA, Voogd PJ, Breimer DD. Liquid chromatographic determination of nifedipine in plasma and of its main metabolite in urine. J Chromatogr 1984; 308: 209-216.
15. Reitberg DP, Love SJ, Quercia GT, Zinny MA. Effect of food in nifedipine pharmacokinetics. Clin Pharmacol Ther 1987; 42: 72-75.
16. Palma-Aguirre JA, Rosas-Alcazar G, Rodriguez JM, Leon-Urrea F, Montoya-Cabrera MA. Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers. Arch Invest Med 1989; 20: 129-135.
17. Tateichi T, Ohashi K, Sudo T, et al. Dose-dependent effect of diltiazem on the pharmacokinetics of nifedipine. J Clin Pharmacol 1989; 29: 994-997.
18. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci 1992; 81: 309-312.
19. WinNonlin User's Guide. Scientific Consulting; Lexington, Kentucky, USA. 1995.
20. Banzet O, Colin JN, Thibonnier M, Singlas E, Alexandre JM, Corvol P. Acute antihypertensive effect and pharmacokinetics of a tablet preparation of nifedipine. Eur J Clin Pharmacol 1983; 4: 145-150.
21. De Wazies I, Cugnenc Ph, Yang CS, Leroux J-P, Beaune PH. Cytochrome P450 isoenzymes, ipoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 253: 387-394.
22. Gibaldi M, Perrier D. Pharmacokinetics. Marcel Dekker: New York, 1975, 243-250.
23. Ahsan CH, Renwick AG, Macklin B, Challenor VF, Waller DG, George CF. Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol 1991; 31: 399-403.
24. Lou YC, Ying L, Bertilisson L, Sjoqvist F. Low frequency of slow debrisoquin hydroxylation in a native Chinese population. Lancet 1987; 2: 852-853.
25. Hora Y, Nakano M, Ishizaki T. Metroprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46: 198-207.
26. De Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-598.
27. Schellens JHM, Soons PA, Breimer DD. Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol 37: 2507-2510.
28. Guengerich FP, Human cytochrome P450 enzymes, In Cytochrome P450 Oritiz de Montellano PR (ed.) 2nd edn. Plenum Press: New York, 1995. 473-535.
29. Shimada T, Yamazaki H, Mimura M, Inui Y, Gengerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
30. FabreG, Rahmani R, Placidi M, et al. Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. Biochem Pharmacol 1988; 37: 4389-4397.
31. Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha, 25-dihydroxyvitamin D3. Mol Pharmacol 1997; 51: 741-54.
32. Tateishi T, Watanabe M, Moriya H, Yamaguchi S, Sato T, Kobayashi S. No ethnic differences between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem Pharmacol 1999; 57: 935-939.
33. Lin KM, Lau JK, Smith R, Phillips P, Antal W, Poland RE. Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers. Psychopharmacology 1988; 96: 365-369.
34. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in human. J Pharmacokinet Biopharm 1996; 24: 475-490.